Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A combinatorial strategy for treating KRAS-mutant lung cancer.

Nature - 30 Jun 2016

Manchado Eusebio, Weissmueller Susann, Morris John P, Chen Chi-Chao, Wullenkord Ramona, Lujambio Amaia, de Stanchina Elisa, Poirier John T, Gainor Justin F, Corcoran Ryan B, Engelman Jeffrey A, Rudin Charles M, Rosen Neal, Lowe Scott W

Abstract excerpt

Therapeutic targeting of KRAS-mutant lung adenocarcinoma represents a major goal of clinical oncology. KRAS itself has proved difficult to inhibit, and the effectiveness of agents that target key KRAS effectors has been thwarted by activation of compensatory or parallel pathways that limit their efficacy as single agents. Here we take a systematic approach towards identifying combination targets for trametinib, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Feedback, Physiological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imidazoles

Share to Mitogen-Activated Protein Kinase Kinases

Share to Pyridazines

Share to Pyridones

Share to Pyrimidinones

Share to Receptor, Fibroblast Growth Factor, Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 27338794
DOI: 10.1038/nature18600
PMCID: PMC4939262

Genes

KRAS
FGFR1
FRS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A combinatorial strategy for treating KRAS-mutant lung cancer.PMID 27338794Read ↗

Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.Semantic proximity Read ↗

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read ↗

Targeting KRAS mutant lung cancer: light at the end of the tunnel.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.Semantic proximity Read ↗

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.Semantic proximity Read ↗

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and RestrictionsSemantic proximity Read ↗

Overcoming KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibitionSemantic proximity Read ↗

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.